UB654
ProductTrastuzumab injection
Strength150mg/vial
IndicationsBreast cancer; Gastric cancer
TherapeuticsOncology
GMPCN - NMPA
RegistrationChina
ModalitiesAntibody
Exclusive Summary
- · Herceptin (Trastuzumab) biosimilar
- · Bringing new high-quality option for clinical anti-HER2 Treatment
- · The first commercial biologic of Oncology BU, got NMPA approval in 2023 Q1
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →